PMM.69 The role of continuous audit in monitoring care for women with diabetes in pregnancy; 4 years experience in a high-risk London unit

2014 ◽  
Vol 99 (Suppl 1) ◽  
pp. A145.2-A145
Author(s):  
JLD Currie ◽  
B Black ◽  
A Mustapha ◽  
N Settle ◽  
H Brownhill ◽  
...  
2021 ◽  
pp. 1753495X2110147
Author(s):  
Adrian Li ◽  
Anna Brackenridge

The risks associated with diabetes in pregnancy include congenital anomalies, stillbirth and miscarriage, and correlate with glycaemia. The optimisation of diabetes during pregnancy is therefore both challenging and essential. Technology has revolutionised how clinicians and patients manage diabetes. This review article focuses on the role of continuous glucose monitoring (CGM) in pregnancy, assessing the evidence available and providing an update on current guidance.


2022 ◽  
Vol 226 (1) ◽  
pp. S183-S184
Author(s):  
Layna Lu ◽  
Elizabeth Soyemi ◽  
Karolina Leziak ◽  
Charlotte M. Niznik ◽  
Melissa A. Simon ◽  
...  

Author(s):  
Abdelrahim Alqudah ◽  
Kelly-Ann Eastwood ◽  
Djurdja Jerotic ◽  
Naomi Todd ◽  
Denise Hoch ◽  
...  

AbstractContextDiabetes in pregnancy is associated with numerous complications, however the mechanisms are still poorly understood.ObjectiveTo investigate the role of new angiogenesis markers, FKBPL and SIRT-1, in pre-gestational (type 1 diabetes, T1D) and gestational diabetes (GDM).Design and interventionPlacental FKBPL, SIRT-1, PlGF and VEGF-R1 protein expression was determined from pregnant women with GDM or T1D, and in first trimester trophoblast cells exposed to high glucose and varying oxygen concentrations. Endothelial cell function was assessed in high glucose conditions and FKBPL overexpression.Settings and ParticipantsHuman placental samples from pregnant women with GDM (n=6) or T1D (n=8) were collected to assess FKBPL and SIRT-1 protein expression compared to non-diabetic controls.Main outcome measuresTo determine the role of placental FKBPL and/or SIRT-1 in diabetic pregnancies, in first trimester trophoblasts and endothelial cell function in high-glucose environment.ResultsPlacental FKBPL protein expression was downregulated in T1D (FKBPL; p<0.05) whereas PlGF/VEGF-R1 were upregulated (p<0.05); correlations adjusted for gestational age were also significant. In the presence of GDM, only SIRT-1 (p<0.001) was significantly downregulated even when adjusted for gestational age (r=-0.92, p=0.001). FKBPL and SIRT-1 were also downregulated in ACH-3P cells in high glucose conditions and 6.5%/2.5% oxygen concentrations (p<0.05). FKBPL overexpression in HUVECs reduced tubule formation compared to empty vector control, in high glucose conditions (junctions; p<0.01, branches; p<0.05).ConclusionsFKBPL and/or SIRT-1 downregulation in response to diabetes may have a role in the development of vascular dysfunction in pregnancy, and associated complications such as preeclampsia.


2014 ◽  
Vol 38 (5) ◽  
pp. S55
Author(s):  
Danielle Stringer ◽  
Leigh Minuk ◽  
Laura Kerr ◽  
Rachelle Govia ◽  
Maureen Heaman ◽  
...  

EMJ Diabetes ◽  
2020 ◽  

The management of gestational diabetes mellitus (GDM) involves screening (or universal testing), a diagnostic oral glucose tolerance test, patient counselling/education, gestational weight management and medical nutrition therapy, and self-monitoring of blood glucose levels with regular glycaemia reviews. This is in addition to pharmacological treatment, often insulin therapy, if glycaemia is above target. Females with GDM receive more frequent ultrasound testing to assess fetal growth, and birth is planned and not usually allowed to go much past term. A range of challenges continue to arise in GDM management including screening approaches and diagnostic criteria, dealing with the increasing numbers of females diagnosed, weight and glycaemic targets, the long-term safety of oral antihyperglycaemic agents for the offspring, particularly metformin, and adjunct medication for complication prevention. GDM management involves additional complexities including differentiating between those with likely undiagnosed Type 2 diabetes mellitus (diabetes in pregnancy), how to manage females with high glucose early in pregnancy less than diabetes in pregnancy, and identifying females with rare causes, for example monogenic diabetes or new Type 1 diabetes mellitus in pregnancy. While the management of GDM has evolved from identifying females at high risk of progressing to Type 2 diabetes mellitus, to greater focus on improving pregnancy outcomes, females with prior GDM and their offspring have the highest need for follow-up and prevention strategies. To date, follow-up and intervention remains limited for this high-risk group for both diabetes and cardiovascular disease. Follow-up in these females is particularly important for the next pregnancy, especially as GDM prevention from the second trimester onwards remains another continuing challenge.


2014 ◽  
Vol 28 (15) ◽  
pp. 1856-1863 ◽  
Author(s):  
Badreldeen Ahmed ◽  
Mandy Abushama ◽  
Majeda Khraisheh ◽  
J. Dudenhausen

Sign in / Sign up

Export Citation Format

Share Document